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ABSTRACT: Biallelic inactivating germline mutations in the base excision repair MUTYH (MYH) gene 
have been shown to predispose to MUTYH-associated polyposis (MAP), which is characterized by 
multiple colorectal adenomas and carcinomas. In this study, we successfully prepared highly 
homogeneous human MUTYH type 2 recombinant proteins and compared the DNA glycosylase 
activity of the wild-type protein and fourteen variant-type proteins on adenine mispaired with 8-
hydroxyguanine, an oxidized form of guanine. The adenine DNA glycosylase activity of the p.I195V 
protein, p.G368D protein, p.M255V protein, and p.Y151C protein was 66.9%, 15.2%, 10.7%, and 
4.5%, respectively, of that of the wild-type protein, and the glycosylase activity of the p.R154H, 
p.L360P, p.P377L, p.452delE, p.R69X, and p.Q310X proteins as well as of the p.D208N negative 
control form was extremely severely impaired. The glycosylase activity of the p.V47E, p.R281C, 
p.A345V, and p.S487F proteins, on the other hand, was almost the same as that of the wild-type 
protein. These results should be of great value in accurately diagnosing MAP and in fully 
understanding the mechanism by which MUTYH repairs DNA in which adenine is mispaired with 
8-hydroxyguanine.  ©2010 Wiley-Liss, Inc. 
KEY WORDS: base excision repair, 8-hydroxyguanine, MUTYH, MUTYH-associated polyposis, MAP, 
DNA glycosylase, colorectal cancer 
 
INTRODUCTION 
8-Hydroxyguanine (8-OHG) is an oxidized form of guanine (Kasai and Nishimura, 1991), and because 8-OHG 
can pair with adenine as well as cytosine, formation of 8-OHG in DNA causes a G:C to T:A transversion mutation 
(Shibutani et al., 1991). MUTYH protein (MIM# 604933), also known as MYH protein, is a DNA glycosylase that 
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catalyzes the removal of adenine mispaired with 8-OHG in double-stranded DNA (Slupska et al., 1999; Shinmura et 
al., 2000; Tao et al., 2008). Two major MUTYH proteins, i.e., type 1 and type 2, are expressed in human cells as a 
result of the presence of multiple transcription initiation sites and alternative splicing of mRNA transcripts (Takao et 
al., 1999; Ohtsubo et al., 2000). Type 1 is composed of 535 amino acids, and because it contains a mitochondrial 
targeting signal (MTS) in its N-terminal, it is localized in the mitochondria. Type 2 is composed of only 521 amino 
acid, because it lacks the N-terminal 14 amino acids of type 1, which contain the MTS, and as a result type 2 is 
localized in the nucleus (Takao et al., 1999; Ohtsubo et al., 2000). The excisional repair activity of the type 2 protein 
is greater than that of the type 1 protein under certain conditions (Shinmura et al., 2000). 
Biallelic inactivating germline mutations in the MUTYH gene predispose to MUTYH-associated polyposis 
(MAP; MIM# 608456), an autosomal recessive disorder characterized by multiple colorectal adenomas and 
carcinomas (Al-Tassan et al., 2002; Jones et al., 2002; Sampson et al., 2003; Sieber et al., 2003). Since the diagnosis 
of MAP depends on the level of repair activity of the MUTYH variants encoded in the two MUTYH alleles of the 
patient and the presence of the clinical phenotype characteristic of MAP, even when MUTYH gene variations are 
present in a patient, information on the level of repair activity of the MUTYH variants is indispensable to making 
the diagnosis of MAP. However, even though more than 80 MUTYH variants have been described in the MUTYH 
gene in colorectal polyposis and colorectal cancer patients (reviewed in Cheadle and Sampson, 2007; Vogt et al., 
2009), the effect of only a small number of variations on human MUTYH protein activity has been investigated 
(Wooden et al., 2004; Bai et al., 2005; Bai et al., 2007; Ali et al., 2008; Kundu et al., 2009; Forsbring et al., 2009; 
Molatore et al., 2010). One of the reasons for not investigating the effect of more variations is that human MUTYH 
recombinant proteins cannot be efficiently overexpressed and purified in Escherichia coli (E. coli) and baculovirus 
cultures or in a cell-free system. Thus, even in previous investigations of variant MUTYH proteins, the purified 
protein fraction also contained multiple other proteins, judging from the photographs of the SDS-PAGE gels. The 
authors of one paper (Bai et al., 2005) estimated that the purity of the GST-MUTYH fusion proteins used in the 
analysis was approximately 15%. Too much amount of contamination by other proteins can interfere with accurate 
determination of the repair activity of variant MUTYH proteins. Thus, improvement of the production and 
purification system is needed to enable accurate evaluation of the repair activity of variant MUTYH proteins. 
Moreover, since somatic APC (MIM# 611731) mutations occur in the nuclear DNA of a high proportion of MAP 
tumors (Al-Tassan et al., 2002), it is preferable to evaluate the repair activity of the type 2 protein localized in the 
nucleus, not the type 1 mitochondrial protein. However, except for the study by Molatole et al. (2010), the repair 
activity of variants of the type 1 mitochondrial MUTYH form, not the type 2 nuclear form, has been studied in 
previous studies. Therefore, in the present study we established an experimental system for the purification of 
MUTYH type 2 recombinant proteins and evaluated 14 type 2 variants, i.e., p.V47E, p.Y151C, p.R154H, p.I195V, 
p.M255V, p.R281C, p.A345V, p.L360P, p.G368D, p.P377L, p.452delE, p.S487F, p.R69X, and p.Q310X, which 
correspond to type 1 proteins p.V61E, p.Y165C, p.R168H, p.I201V, p.M269V, p.R295C, p.A359V, p.L374P, 
p.G382D, p.P391L, p.466delE, p.S501F, p.R83X, and p.Q324X, respectively. All of the above are MUTYH variants 
that have been identified in patients with colorectal polyposis and/or with colorectal cancer (Halford et al., 2003; 
Sieber et al., 2003; Aceto et al., 2005; Aretz et al., 2006; Kanter-Smoler et al., 2006; Lejeune et al., 2006; Peterlongo 
et al., 2006; Russell et al., 2006; Yanaru-Fujisawa et al., 2008). This study assessed the adenine excisional activity 
of a larger number of MUTYH variants than in previous studies, and the repair activity of the type 2 protein of 11 of 
the 14 MUTYH variants (p.V47E, p.R154H, p.I195V, p.M255V, p.R281C, p.A345V, p.L360P, p.P377L, p.S487F, 
p.R69X, and p.Q310X) was examined for the first in this study. 
MATERIALS AND METHODS 
Plasmid construction 
The human MUTYH type 2 cDNA sequence was inserted into a pET25b(+) expression vector (Novagen, 
Darmstadt, Germany). The expression vector for 13 missense-type variants was generated by site-directed 
mutagenesis with a QuikChange Site-directed Mutagenesis kit (Stratagene, La Jolla, CA). The expression vector for 
p.R69X and p.Q310X types were constructed by inserting MUTYH cDNA sequence (nucleotides 1-204 and 1-927, 
respectively) into the pET25b(+) expression vector. All vectors were confirmed by DNA sequencing with a BigDye 
Terminator Cycle Sequencing Reaction Kit (Applied Biosystems, Tokyo, Japan) and an ABI 3100 Genetic Analyzer 
(Applied Biosystems). DNA Glycosylase Activity of 14 MUTYH Variants  E1863 
 
 
Preparation of the recombinant MUTYH proteins 
E. coli BL21-CodonPlus (DE3)-RP competent cells (Stratagene) were transformed with the MUTYH-pET25b 
vector and cultured at 37°C until an A600 of 0.6. After incubation with 0.1 mM IPTG at 15°C for 12 h, MUTYH-His6 
protein was purified with TALON metal affinity resins (Clontech, Palo Alto, CA) and a TALON 2-ml disposable 
gravity column (Clontech). The protein was then dialyzed against buffer containing 10 mM sodium phosphate (pH 
7.6), 50 mM NaCl, 0.5 mM DTT, 0.1 mM EDTA, 0.5 mM PMSF, 2 μg/ml pepstatin, 2 μg/ml leupeptin, 50 μM 
chymostatin, and 10% glycerol. The quality and concentration of MUTYH proteins were determined by using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and Image J software (National Institutes of 
Health, Bethesda, MD). 
 
Western blot analysis 
Purified recombinant protein was mixed with an equal volume of 2x SDS sample buffer and boiled.
 A 2 µg 
protein was subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and electrophoretically transferred to a 
polyvinylidene
 difluoride membrane (GE Healthcare Bio-Science Corp., Piscataway,
 NJ). The membrane was 
blocked with non-fat milk and incubated
 with an anti-MUTYH polyclonal antibody (Ohtsubo et al., 2000). After 
washing, the membrane was incubated with an anti-rabbit
 HRP-conjugated secondary antibody (GE Healthcare
 Bio-
Science Corp.). The membrane was then washed, and immunoreactivity was visualized with
  an ECL Plus 
chemiluminescence system (GE Healthcare Bio-Science Corp.). 
 
DNA cleavage activity assay 
30-mer oligonucleotides containing and not containing a single 8-OHG (5'-CTG GTG GCC TGA C[8-OHG or 
T]C ATT CCC CAA CTA GTG-3') were chemically synthesized and purified by PAGE (Japan Bio Services, 
Saitama, Japan). Complementary oligonucleotides containing an adenine opposite the 8-OHG or T were 
32P-labeled 
at the 5' terminus with a MEGALABEL kit (Takara, Osaka, Japan) and a [γ-
32P]ATP (PerkinElmer, Tokyo, Japan), 
and then annealed to oligonucleotides containing a single 8-OHG or T. The reaction mixture containing 20 mM 
sodium phosphate (pH 7.6), 100 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA, 5 μM ZnCl2, 1.5% glycerol, 2.5 nM 
labeled oligonucleotide, 50 μg/ml BSA, and purified MUTYH protein was incubated at 37°C, and the mixture was 
treated with 0.1 M NaOH at 95°C for 4 min. After adding denaturing formamide dye to the mixture, it was heated at 
95°C for 3 min, and subjected to 20% PAGE. A 
32P-labeled marker oligonucleotide was used as a size marker for 
the cleavage products. The radioactivity of intact and cleaved oligonucleotides was quantified by using an FLA-
3000 fluoroimage analyzer (Fuji Film, Tokyo, Japan) and ImageGauge software (Fuji Film) (Goto et al., 2009). 
 
Active site titration and evaluation of the rate constant kf 
The active site titration and evaluation of the rate constant were performed as described previously (Fersht, 1985; 
Kundu et al., 2009). A 100 ng amount of total proteins was incubated at 37°C for 0 - 30 min with 5 nM 8-OHG 
containing substrate and the cleavage products were monitored. To determine the amplitude of the burst (A0), which 
is proportional to the active protein fraction concentration, the data were fitted to equation (1): 
[P]t = A0[1-exp(-kbt)] + klt      ( 1 )                                                                                
where [P]t is the cleavage product concentration at time t and kb and kl are the rate constants of the burst phase 
and the linear phase, respectively. 
 Rate constant, kf, was evaluated under single-turnover conditions. A 10 nM concentration of active MUTYH 
enzymes was incubated at 37°C for 0 - 15 min with 2.5 nM 8-OHG containing substrate and the cleavage products 
were monitored. To estimate the kf, the data were fitted to equation (2): 
[P]t = A0[1-exp(-kft)]        ( 2 )                                                                                  
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Mutation nomenclature and reference sequence 
Mutation nomenclature is according to den Dunnen and Antonarakis (2000) and den Dunnen and Paalman 
(2003). The reference sequence for the MUTYH gene encoding type 2 protein is accession number 
NM_001048174.1.  The nucleotide numbering system uses the A of the ATG translation initiation start site as 
nucleotide +1. 
 
 
 
Figure 1. Measurement of the adenine DNA glycosylase activity of wild-type MUTYH type 2 protein. (A) Purification of wild-
type MUTYH type 2 protein resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie Brilliant 
Blue. Lysates of E. coli culture without or with IPTG induction and purified MUTYH type 2 protein are shown. The arrow points 
to the MUTYH-His6 protein band. (B) Western blot of purified wild-type MUTYH type 2 protein tagged with His6. MUTYH-
His6 protein is indicated by the arrow. Purified recombinant NEIL1 (MIM# 608844)-His6 protein, which was prepared by using 
pET25b(+) vector (Novagen) and E. coli BL21-CodonPlus (DE3)-RP cells (Stratagene) previously (Shinmura et al., 2004), was 
included as a negative control. (C) The DNA glycosylase activity of MUTYH type 2 protein on double-stranded DNA containing 
an A:8-hydroxyguanine (8-OHG). The MUTYH type 2 protein and a 
32P-labeled double-stranded oligonucleotides containing or 
not containing a single 8-OHG mispair were incubated and subjected to 20% PAGE. The intact 30-mer oligonucleotides and 
cleavage products are indicated by the arrows. Heat-inactivation of the MUTYH protein was accomplished by heating the protein 
at 100°C for 5 min. 8G means 8-hydroxyguanine. (D) Protein concentration dependency of cleavage of DNA containing an A:8-
OHG by MUTYH type 2 protein. The MUTYH protein (2, 8, and 20 ng) was incubated at 37°C for 15 min with a 30-mer 
oligonucleotide containing an A:8-OHG or A:T (50 fmole). The amount of cleavage products as a proportion of total 
oligonucleotides was calculated as % incision. (E) Time-course assay of cleavage of DNA containing an A:8-OHG by MUTYH 
type 2 protein. The 8 ng amount of MUTYH type 2 protein was incubated at 37°C for 0 - 60 min with double-stranded 
oligonucleotide containing an A:8-OHG (50 fmole). The % incision valves are means ± standard errors of data from three 
independent experiments. DNA Glycosylase Activity of 14 MUTYH Variants  E1865 
 
 
 
Figure 2. Purification of variant-type MUTYH type 2 recombinant proteins. Each protein was overexpressed and purified under 
conditions essentially the same as used for the wild-type (WT) protein. Representative results of expression and purification of 
MUTYH proteins resolved by SDS-PAGE and stained with Coomassie Brilliant Blue are shown. ‘–’ and ‘+’ mean absence and 
presence, respectively, of IPTG induction, and ‘Pur’ means purified MUTYH type 2 proteins. The arrow points to the MUTYH-
His6 protein band. The purification level is indicated below the SDS-PAGE panels. 
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RESULTS 
To overcome the difficulty of preparing highly purified recombinant MUTYH proteins, in this study, we used a 
pET25b(+) expression vector and BL21-CodonPlus (DE3)-RP E. coli host cells for induction of MUTYH 
expression and a TALON metal affinity resin and gravity column for purification of the MUTYH proteins. Wild-
type human MUTYH type 2 protein tagged with His6 at its C-terminus was successfully overexpressed in E. coli and 
purified to approximately 90% homogeneity (Figure 1A). The specificity of the purified MUTYH protein was 
confirmed by Western blotting with anti-MUTYH polyclonal antibody (Figure 1B). Their molecular size of 
approximately 61 kDa was determined by SDS-PAGE / Coomassie Brilliant Blue (CBB) staining and Western 
blotting, and it corresponded to their size calculated from the cDNA sequence. The DNA glycosylase activity of the 
wild-type MUTYH protein was tested by determining its capacity to cleave a double-stranded oligonucleotide 
containing an adenine mispaired with 8-OHG. The cleavage products were analyzed on a denaturing polyacrylamide 
gel, and their mobility was compared with that of a marker oligonucleotide. No clear cleavage products were 
detected when oligonucleotide containing an unmodified A:T base pair was exposed to the MUTYH protein, but 
cleavage products having the same mobility as the marker oligonucleotide were detected when MUTYH proteins 
were allowed to react with oligonucleotide containing an A:8-OHG base pair (Figure 1C). No cleavage was detected 
when allowed to react after heat-inactivation of the MUTYH protein (Figure 1C). The amount of cleavage products 
was calculated as percent of total oligonucleotides and expressed as % incision, and the % incision of protein 
substrate containing an A:8-OHG mispair increased in a protein-concentration–dependent manner (Figure 1D). The 
time-course assay of the cleavage activity of MUTYH protein on substrate containing an A:8-OHG mispair 
indicated that the amount of cleavage products peaked within 5 min and was almost constant from 5 min to 60 min 
(Figure 1E). The results showed that highly purified wild-type MUTYH type 2 protein had been obtained with our 
expression and purification system, and the adenine DNA glycosylase activity of the protein on an A:8-OHG 
mispair was satisfactorily detected by our assay. We therefore decided to apply our experimental systems to 
assessment of the adenine DNA glycosylase activity of various MUTYH variant proteins. 
 
 
 
Figure 3. Measurement of the adenine DNA glycosylase activity of variant MUTYH type 2 proteins. (A) Representative results 
of DNA cleavage assays of MUTYH variant proteins are shown. MUTYH proteins (130 fmole) were allowed to act on double-
stranded oligonucleotide containing a single A:8-OHG (8G) mispair at 37°C for 15 min. The reaction mixture was analyzed by 
20% PAGE. A 
32P-labeled marker oligonucleotide was used as a size marker for the cleavage products. The intact 30-mer 
oligonucleotides and cleavage products are indicated by the arrows. (B) Time-course assay of cleavage of DNA containing an 
A:8-OHG by MUTYH type 2 protein. MUTYH type 2 proteins (130 fmole) were incubated at 37°C for 0 - 45 min with double-
stranded oligonucleotide containing an A:8-OHG (50 fmole). The amount of cleavage products as a proportion of total 
oligonucleotides was calculated as % incision, and the % incision of each variant-type MUTYH protein is shown relative to that 
of wild-type (WT) MUTYH protein, which has been set equal to 100. The % incision valves are means ± standard errors of data 
obtained from three independent experiments in which three independently prepared MUTYH proteins were used. DNA Glycosylase Activity of 14 MUTYH Variants  E1867 
 
Table 1.    DNA glycosylase activity of 14 variants of MUTYH type 2 protein on DNA containing adenine mispaired with 
8-hydroxyguanine 
 
MUTYH type 2 
protein  Type of mutation
a  Purified protein yield 
(ng) per 10 ml culture
b  Relative % incision
c 
WT   4365, 3562, 3454  100 
p.D208N negative  control  2073, 1826, 1808  extremely severely defective 
p.V47E c.140T>A,  missense  1018, 1893, 1916  128.1±5.20  
p.Y151C c.452A>G,  missense  5485, 4779, 2835  4.5±0.21 
p.R154H c.461G>A,  missense  894, 1501, 2109  extremely severely defective 
p.I195V c.583A>G,  missense  1733, 1102, 671  66.9±0.35 
p.M255V c.763A>G,  missense  2446, 1726, 2488  10.7±0.47 
p.R281C c.841C>T,  missense  912, 934, 447  103.0±1.39 
p.A345V c.1034C>T,  missense  2564, 2435, 3864  103.5±5.43 
p.L360P c.1079T>C,  missense  152, 303, 120  extremely severely defective 
p.G368D c.1103G>A,  missense  2486, 1246, 2270  15.2±0.71 
p.P377L c.1130C>T,  missense  885, 626, 430  extremely severely defective 
p.452delE  c.1353_1355delGGA, 
inframe deletion 
822, 614, 364  extremely severely defective 
p.S487F c.1460C>T,  missense  1099, 984, 706  102.8±2.31 
p.R69X c.205C>T,  nonsense  6289, 5245, 6289  extremely severely defective 
p.Q310X c.928C>T,  nonsense  918, 5726, 2771  extremely severely defective 
aThe reference sequence for the MUTYH gene encoding type 2 protein is accession number NM_001048174.1. 
bAmount of MUTYH proteins purified from 10 ml of E. coli culture expressing MUTYH type 2 protein. Each protein was 
purified three times and has been listed in this table. 
cThe DNA cleavage activity of MUTYH protein was measured under conditions of 37°C for 15 min. The amount of 
cleavage products as a proportion of total oligonucleotides was calculated as % incision, and the % incision of each 
variant-type MUTYH protein is shown relative to that of wild-type (WT) MUTYH protein, which has been set equal to 
100. Values are means ± standard errors of data obtained from three independent experiments in which three 
independently prepared MUTYH proteins were used. 
 
 
Fourteen MUTYH variants that had previously been identified in patients with colorectal polyposis and/or 
colorectal cancer were selected, and their expression vectors were prepared by site-directed mutagenesis. Since the 
Asp222 in MUTYH type 1 is the active site, and the p.D222N mutant is known not to have DNA glycosylase 
activity (Wooden et al., 2004), we prepared a type 2-p.D208N construct corresponding to type 1-p.D222N as a 
negative control. A total of 15 MUTYH type 2 proteins were successfully expressed and purified to a high level of 
homogeneity (Figure 2). Their molecular sizes determined by SDS-PAGE / CBB staining corresponded with their 
sizes calculated from their cDNA sequences. Each MUTYH variant protein was almost always reproducibly 
obtained in the three independent protein preparation (Table 1). Next, we compared the DNA glycosylase activity of 
each variant protein on oligonucleotide containing an A:8-OHG mispair with that of the wild-type MUTYH type 2 
protein (Figure 3 and Table 1). As expected, no clear cleavage products were detected when any of the variant 
proteins were allowed to act on oligonucleotide containing an unmodified A:T base pair (Figure 3). The adenine 
DNA glycosylase activity of the MUTYH variant proteins on oligonucleotide containing an A:8-OHG mispair 
varied (Figure 3 and Table 1). The adenine DNA glycosylase activity of the p.V47E, p.R281C, p.A345V, and 
p.S487F proteins on the A:8-OHG substrate under conditions of 37°C for 15 min were similar to that of the wild-
type protein or only slightly different (102.8% - 128.1%, with activity of the wild-type protein set equal to 100%), 
whereas p.I195V protein exhibited slightly lower glycosylase activity (66.9%). The p.Y151C protein, p.M255V 
protein and p.G368D protein exhibited only 4.5%, 10.7%, and 15.2%, respectively, of the glycosylase activity of the 
wild-type protein, and the adenine DNA glycosylase activity of the p.R154H, p.L360P, p.P377L, p.452delE, 
p.R69X, and p.Q310X proteins as well as of the p.D208N negative control protein was almost at the background E1868  Goto  et  al. 
level. We also attempted to determine whether the recombinant type 1 variant proteins had a level of repair activity 
that was similar to that of the corresponding type 2 proteins. We randomly chose type 1-p.R168H and type 1-
p.S501F, which correspond to type 2-p.R154H and type 2-p.S487F, respectively, and found that the activity level of 
the type 1 and type 2 proteins of at least these two MUTYH variants in comparison with the wild-type protein is 
similar (Supp. Figure S1A-E). We also estimated the rate constant kf of some type 2 proteins on the A:8-OHG 
substrate after correction for the active enzyme fraction as described previously (Fersht, 1985; Kundu et al., 2009). 
The rate constant for adenine excision by wild-type protein was 0.524, and similar to the constant for p.R281C (kf = 
0.489) (Table 2). However, the kf value of p.M255V was 0.024 and more than 20-fold lower than that of the wild-
type protein, indicating that the glycosylase activity of p.M255V was severely reduced. The above findings indicate 
that the adenine DNA glycosylase activity of nine of the 14 MUTYH type 2 variant proteins tested is severely 
impaired. 
 
 
 
Table 2.    Active yield and rate constant kf evaluated for MUTYH type 2 protein on DNA containing adenine mispaired 
with 8-hydroxyguanine 
 
MUTYH type 2 protein  Active protein yield (μg) per 1L culture
a  kf (min
-1)
b 
WT 2706,  1248,  2045    0.524±0.034 
p.M255V  58, 72, 75  0.024±0.004 
p.R281C 944,  1128,  751  0.489±0.044 
aValues were obtained by incubating 100 ng of total proteins with 5 nM of substrate. Results obtained with three separate protein 
preparations are shown. 
bValues were obtained by incubating 10 nM of active MUTYH enzyme and 2.5 nM of substrate. Values are means ± standard 
errors of data obtained from three independent experiments using independently prepared proteins. 
 
 
DISCUSSION 
The cumulative results of recent screenings of colorectal polyposis patients for MUTYH mutations have revealed 
many MUTYH gene variants (reviewed in Cheadle and Sampson, 2007; Vogt et al., 2009), but the repair activity of 
the type 2 protein of most of the variants has never been tested. In this study we improved the method of expressing 
and purifying the recombinant MUTYH type 2 proteins and assessed the adenine DNA glycosylase activity of 
various type 2 proteins. The results revealed that the p.V47E, p.R281C, p.A345V, and p.S487F proteins largely 
retain adenine removing activity, but that the adenine removing activity of the p.I195V protein is mildly impaired 
and the activity of the p.Y151C, p.R154H, p.M255V, p.L360P, p.G368D, p.P377L, p.452delE, p.R69X, and 
p.Q310X proteins is severely impaired. This information should be of great help in accurately diagnosing MAP and 
managing MAP patients. 
The adenine DNA glycosylase activity of the type 1 or type 2 MUTYH variants p.Y151C, p.G368D, p.P377L, 
p.452delE, and p.S487F has been assessed previously (Wooden et al., 2004; Ali et al., 2008; Kundu et al., 2009; 
Forsbring et al., 2009; Molatore et al., 2010). The results showed that the repair activity of p.Y151C, p.G368D, 
p.P377L, and p.452delE was impaired while that of p.S487F was retained, findings that were consistent with our 
own, and the consistency confirms the reliability of the results of our study. Interestingly, a slight difference 
(approximately 5% vs. approximately 15%) in repair activity was observed between p.Y151C and p.G368D in our 
study, and the same difference was reported in several previous papers. Nielsen et al. (2009) recently reported 
finding that MAP patients homozygous for a p.G368D allele have a milder clinical phenotype than MAP patients 
homozygous for a p.Y151C allele. The difference in adenine removing activity between the p.Y151C protein and 
p.G368D protein may be related to the difference in clinical phenotype. 
Retention of DNA glycosylase activity by the human MUTYH proteins p.V47E, p.R281C, and p.A345V as well 
as mild impairment of the activity of p.I195V and severe impairment of the activity of p.R154H, p.M255V, 
p.L360P, p.R69X, and p.Q310X were documented for the first time in this study. Although no analyses of crystal DNA Glycosylase Activity of 14 MUTYH Variants  E1869 
 
structure of the MUTYH has been reported, based on the cumulative results of previous studies of the biochemistry 
of MUTYH (reviewed in Cheadle and Sampson, 2007; Ali et al., 2008), p.R154, p.M255, and p.L360 are located in 
regions suspected of being important to catalytic activity or substrate recognition. Moreover, the p.R154, p.M255, 
and p.L360 in MUTYH protein are conserved among E. coli, Mus musculus, Rattus norvegicus, Pan troglodytes, 
Canis familiaris, and Homo sapiens. Substitution of any of these amino acids appears to result in a functional 
abnormality, resulting in severe reduction of adenine DNA glycosylase activity on DNA containing an A:8-OHG 
mispair. The loss of large parts of the MUTYH protein in the frameshift-type variant proteins p.R69X and p.Q310X 
may be responsible for the severe impairment of their adenine removing activity. An amino acid substitution in 
p.V47E, p.R281C, p.A345V, and p.S487F did not greatly affect their adenine DNA glycosylase activity. These 
results are consistent with the prediction of a possible impact of an amino acid substitution on the structure and 
function of MUTYH type 2 protein by the PolyPhen-2 program (http://genetics.bwh.harvard.edu/pph2/index.shtml) 
(Adzhubei et al., 2010). Since p.V47E, p.R281C, p.A345V, and p.S487F are not located in the region suspected of 
being important to catalytic activity or in a well-conserved position of the substrate recognition region, the amino 
acid localization may be one of the reasons for the retention of enzymatic activity. In the future, a crystal structure of 
the MUTYH protein alone and covalently complexed with DNA, in conjunction with the present findings on 
MUTYH variants, should contribute to establishing further correlations between the structure and repair function of 
the MUTYH protein. 
Highly homogeneous MUTYH type 2 recombinant protein was prepared by using the method described in this 
study. As far as we have been able to determine in a review of the literature, the level of purification of the proteins 
in our study was higher than level of purification estimated from the SDS-PAGE images of MUTYH type 1 or type 
2 proteins in previous papers and purification levels described in the other papers. Use of E. coli BL21-CodonPlus 
(DE3)-RP cells, which contain extra copies of the genes that encode the tRNAs of rare E. coli codons, is thought to 
be responsible for the increase in level of MUTYH protein expression, because the MUTYH gene contains many rare 
codons. The expression conditions (temperature and IPTG concentration), combination of expression vector and 
competent cells, and metal-affinity purification conditions are also thought to possibly have contributed to the 
improvement in the level of purification in this study. Since genetic screening of colorectal polyposis patients for 
MUTYH mutations will continue to be performed worldwide, the same as genetic screening for APC mutations 
(reviewed in Lynch et al., 2008), our method of expression and purification of human MUTYH protein should be 
useful for assessing MUTYH variants newly identified by genetic screening as well as MUTYH variants that have 
not been examined. 
As shown in Supp. Figure S1E, the activity level of the type 1 and type 2 proteins of two MUTYH variants in 
comparison with the wild-type protein was similar. Although comparisons were not made for the other variants, it 
may not always be necessarily to study the type 2 form when analyzing MUTYH protein. However, since type 2, 
and not type 1, is a nuclear form (Takao et al., 1999; Ohtsubo et al., 2000), and somatic APC mutations occur in the 
nuclear DNA of MAP tumors (Al-Tassan et al., 2002), we think that evaluation of type 2 variants is likely to be 
more preferable when we investigate the possible pathogenic role of MUTYH in MAP. Assessment of the 
glycosylase activity level of the wild-type type 1 and type 2 proteins showed that the activity of type 2 was greater 
than that of type 1 (Figure 1 and Supp. Figure S1), a finding that is consistent with a previous report (Shinmura et 
al., 2000). The reason for the difference in the catalysis of adenine excision between the type 1 and type 2 proteins is 
unclear. One point that requires caution is that there is evidence that the type 1 protein is processed during 
mitochondrial transport in cells and the mature form of the protein never been identified, and thus the repair activity 
of the full-length type 1 may not necessarily reflect the activity in vivo. With regard to the method of evaluating 
MUTYH variant proteins, since MUTYH possesses suppressive activity against G:C to T:A mutations caused by 8-
OHG (Yamane et al., 2003) and biallelic MUTYH inactivation leads to somatic APC mutation in MAP tumors (Al-
Tassan et al., 2002), analysis of the mutation rate of the APC gene in MUTYH variant-expressing cells may be an 
alternative way of evaluating the level of repair activity of a MUTYH variant. A combination of mutation rate 
analysis and DNA glycosylase analysis would provide more definitive proof of the pathogenicity of a MUTYH 
variant. 
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Supp. Figure S1. Measurement of DNA glycosylase activity of MUTYH type 1 protein. (A) Purification of wild-type MUTYH 
type 1 protein resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie Brilliant Blue (CBB). 
The human MUTYH type 1 cDNA sequence was inserted into a pET25b(+) expression vector (Novagen, Darmstadt, Germany). 
E. coli BL21-CodonPlus (DE3)-RP competent cells (Stratagene, La Jolla, CA) were transformed with the MUTYH-pET25b 
vector and cultured at 37°C until an A600 of 0.6. After incubation with 0.1 mM IPTG at 20°C for 12 h, MUTYH-His6 protein was 
purified with TALON metal affinity resins (Clontech, Palo Alto, CA) and a TALON 2-ml disposable gravity column (Clontech). 
The protein was then dialyzed against buffer containing 10 mM sodium phosphate (pH 7.6), 50 mM NaCl, 0.5 mM DTT, 0.1 mM 
EDTA, 0.5 mM PMSF, 2 μg/ml pepstatin, 2 μg/ml leupeptin, 50 μM chymostatin, and 10% glycerol. Lysates of E. coli culture 
without or with IPTG induction and purified MUTYH type 1 protein are shown. The arrow points to the MUTYH-His6 protein 
band. (B) Western blot of purified wild-type MUTYH type 1 protein tagged with His6. Purified recombinant NEIL1-His6 protein, 
which was prepared by using pET25b(+) vector (Novagen) and E. coli BL21-CodonPlus (DE3)-RP cells (Stratagene) previously 
(Shinmura et al., 2004), was included as a negative control. Purified recombinant protein was mixed with an equal volume of 2x 
SDS sample buffer and boiled.
  A 2 µg protein was subjected to SDS-PAGE and electrophoretically transferred to a 
polyvinylidene
 difluoride membrane (GE Healthcare Bio-Science Corp., Piscataway,
 NJ). The membrane was blocked with non-
fat milk and incubated
 with an anti-MUTYH polyclonal antibody (Ohtsubo et al., 2000). After washing, the membrane was 
incubated with an anti-rabbit
 HRP-conjugated secondary antibody (GE Healthcare
 Bio-Science Corp.). The membrane was then 
washed, and immunoreactivity was visualized with
 an ECL Plus chemiluminescence system (GE Healthcare Bio-Science Corp.). 
MUTYH-His6 protein is indicated by the arrow. (C) The DNA glycosylase activity of wild-type MUTYH type 1 protein on 
double-stranded DNA containing an A:8-hydroxyguanine (8-OHG). 30-mer oligonucleotides containing and not containing a 
single 8-OHG (5'-CTG GTG GCC TGA C[8-OHG or T]C ATT CCC CAA CTA GTG-3') were chemically synthesized and 
purified by PAGE (Japan Bio Services, Saitama, Japan). Complementary oligonucleotides containing an adenine opposite the 8-
OHG or T were 
32P-labeled at the 5' terminus with a MEGALABEL kit (Takara, Osaka, Japan) and a [γ-
32P]ATP (PerkinElmer, 
Tokyo, Japan), and then annealed to oligonucleotides containing a single 8-OHG or T. The reaction mixture containing 20 mM 
sodium phosphate (pH 7.6), 100 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA, 5 μM ZnCl2, 1.5% glycerol, 2.5 nM labeled 
oligonucleotide, 50 μg/ml BSA, and purified MUTYH protein was incubated at 37°C, and the mixture was treated with 0.1 M E1874  Goto  et  al. 
NaOH at 95°C for 4 min. After adding denaturing formamide dye to the mixture, it was heated at 95°C for 3 min, and subjected 
to 20% PAGE. A 
32P-labeled marker oligonucleotide was used as a size marker for the cleavage products. The radioactivity of 
intact and cleaved oligonucleotides was quantified by using an FLA-3000 fluoroimage analyzer (Fuji Film, Tokyo, Japan) and 
ImageGauge software (Fuji Film) (Goto et al., 2009). The intact 30-mer oligonucleotides and cleavage products are indicated by 
the arrows. Heat-inactivation of the MUTYH protein was accomplished by heating the protein at 100°C for 5 min. 8G means 8-
hydroxyguanine. (D) Time-course assay of cleavage of DNA containing an A:8-OHG by wild-type MUTYH type 1 protein. The 
MUTYH type 1 protein (260 fmole) was incubated at 37°C for 0 - 60 min with double-stranded oligonucleotide containing an 
A:8-OHG (50 fmole). The amount of cleavage products as a proportion of total oligonucleotides was calculated as % incision. 
The % incision values are shown as means ± standard errors of data from three independent experiments. (E) DNA glycosylase 
activities of wild-type MUTYH type 1 protein and their variant proteins on an A:8-OHG substrate. DNA cleavage activities of 
MUTYH type 1 proteins were measured at 37°C for 15 min. The amount of cleavage products as a proportion of total 
oligonucleotides was calculated as % incision, and the % incision of each variant-type MUTYH protein is shown relative to that 
of wild-type (WT) MUTYH protein, which has been set equal to 100. Values are means ± standard errors of data from three 
independent experiments. ND, not detected. 